youtube_live
Q3 2026 earnings ā¢ released ā¢ EPS miss -54.39% ā¢ Revenue miss -5.83%
See resultschevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$15.43
arrow_downward
-0.90%(-0.14) 1D
$15.43
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 6, 4:00:01āÆPM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
$15.68
High
$15.97
Low
$15.12
Mkt. cap
1.52B
Avg. vol.
3.88M
Volume
4.05M
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.19
Beta
0.37
Shares outstanding
101.92M
No. of employees
1K
Open
$15.68
High
$15.97
Low
$15.12
Mkt. cap
1.52B
Avg. vol.
3.88M
Volume
4.05M
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.19
Beta
0.37
Shares outstanding
101.92M
No. of employees
1K
News stories
From web sources and news partners
TradingView
·
1 day ago
H&S in a Falling Channel, Short Toward 7,000 for CAPITALCOM:SPX500 by Audacity618
BigGo Finance
·
2 hours ago
Global AI and Semiconductor Stocks Plunge; S&P 500 Tumbles 4.4% in a Single Day as Markets Watch Whether Three Central Banks Will Raise Rates in December
Quantisnow
·
8 hours ago
Consumer Staples sector performance - S&P 500 consumer staples stocks
www.tmgm.com
·
1 day ago
United States CFTC S&P 500 NC Net Positions up to $-129.4K from previous $-134.4K
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The companyās Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneronās evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1.37K
Founded2010
HeadquartersNovato, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteultragenyx.com